Unigene Gains Milestone in Warner-Lambert Collaboration

Unigene Laboratories Inc. (Fairfield, NJ) has received a $2.5 million milestone payment from Warner-Lambert Co. (Morris Plains, NJ). The payment comes with the successful conclusion of the final pilot human study prior to initiating Phase I studies with an oral calcitonin formulation. The formulation used in the study was based on Unigene's patented technology and was manufactured by Warner-Lambert.

The companies plan to file an Investigational New Drug Application (IND), which will allow the formulation to be tested in humans in the U.S., later this year.

Unigene Laboratories Inc. is a biopharmaceutical company engaged in the research, production, and delivery of therapeutic peptide hormones.

For more information: Warren Levy, President, Unigene Laboratories Inc., 110 Little Falls Rd., Fairfield, NJ 07004-2193. Tel: 973-882-0860. Fax: 973-227-6088.